Tudor Investment Corp
CHRS icon

Tudor Investment Corp’s Coherus Oncology CHRS Stock Holding History

Tudor Investment Corp’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-37,952
Closed -$126K – 2286
2023
Q4 		$126K Sell
37,952
-17,569
-32% -$47.1K ﹤0.01% 2237
2023
Q3 		$208K Buy
55,521
+12,834
+30% +$59.3K ﹤0.01% 2079
2023
Q2 		$182K Buy
42,687
+683
+2% +$4.03K ﹤0.01% 2247
2023
Q1 		$287K Buy
42,004
+5,176
+14% +$40.2K ﹤0.01% 1960
2022
Q4 		$292K Buy
36,828
+13,218
+56% +$102K 0.01% 1918
2022
Q3 		$227K Sell
23,610
-151,480
-87% -$1.53M ﹤0.01% 1976
2022
Q2 		$1.27M Sell
175,090
-13,611
-7% -$118K 0.03% 742
2022
Q1 		$2.44M Sell
188,701
-7,521
-4% -$95.6K 0.06% 458
2021
Q4 		$3.13M Buy
+196,222
New +$3.43M 0.05% 433
2020
Q1 		– Sell
-16,491
Closed -$297K – 1082
2019
Q4 		$297K Buy
+16,491
New +$304K 0.01% 870
2019
Q2 		– Sell
-30,809
Closed -$420K – 1115
2019
Q1 		$420K Buy
+30,809
New +$411K 0.02% 765
2017
Q4 		– Sell
-19,502
Closed -$260K – 1094
2017
Q3 		$260K Sell
19,502
-9,179
-32% -$121K 0.01% 874
2017
Q2 		$412K Buy
28,681
+5,458
+24% +$105K 0.01% 639
2017
Q1 		$491K Buy
23,223
+8,827
+61% +$217K 0.02% 699
2016
Q4 		$405K Buy
14,396
+3,726
+35% +$104K 0.01% 840
2016
Q3 		$286K Sell
10,670
-630
-6% -$17.2K 0.01% 1050
2016
Q2 		$191K Buy
+11,300
New +$212K ﹤0.01% 1417

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Tudor Investment Corp's CHRS Position: Q1 2024 in Review

Tudor Investment Corp sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 37,952 shares — an estimated $126K sold.

Tudor Investment Corp first reported a position in CHRS in Q2 2016 and held it in 17 quarters. The position peaked at $3.13M in Q4 2021. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Tudor Investment Corp reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 37,952 Coherus Oncology shares in Q1 2024, an estimated $126K.
  • Tudor Investment Corp first reported a position in Coherus Oncology in Q2 2016 and held it in 17 quarters.
  • Tudor Investment Corp's Coherus Oncology position peaked at $3.13M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Tudor Investment Corp's 13F filing for Q1 2024, filed 15 May 2024.